Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DS-1103a + DS-3939a |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DS-1103a | DS1103a|DS 1103a | SIRPA Antibody 9 | DS-1103a is an antibody that targets SIRPA and prevents its interaction with CD47, which potentially enhances macrophage-dependent anti-tumor activity (Journal for ImmunoTherapy of Cancer 2022, Vol 10: Suppl 2, 808). | |
| DS-3939a | DS3939a|DS 3939a | MUC1 Antibody 10 | DS-3939a is an antibody-drug conjugate (ADC) comprising an antibody targeting tumor-associated MUC1 (TA-MUC1) linked to a topoisomerase I inhibitor, which potentially induces cell cycle arrest and apoptosis of TA-MUC1-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 6579)). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07739966 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium DS-1103a + DS-3939a DS-3939a + Pembrolizumab DS-3939a Carboplatin + DS-3939a + Pembrolizumab DS-3939a + Pembrolizumab + Pemetrexed Disodium | A Study of DS-3939a in Participants With Solid Tumors | Recruiting | USA | TUR | ITA | FRA | ESP | BRA | BEL | AUT | ARG | 4 |
CKB BOOST